{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:25:17Z","timestamp":1788953117060,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1038\/cdd.2017.129","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T14:31:16Z","timestamp":1502461876000},"page":"2089-2100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-\u03baB in high-grade serous ovarian carcinoma"],"prefix":"10.1038","volume":"24","author":[{"given":"Yuqiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-9342","authenticated-orcid":false,"given":"Changshun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"key":"BFcdd2017129_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM . mTOR signaling in growth control and disease. Cell 2012; 149: 274\u2013293.","journal-title":"Cell"},{"key":"BFcdd2017129_CR2","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","volume":"25","author":"JB Easton","year":"2006","unstructured":"Easton JB, Houghton PJ . mTOR and cancer therapy. Oncogene 2006; 25: 6436\u20136446.","journal-title":"Oncogene"},{"key":"BFcdd2017129_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ygyno.2015.02.003","volume":"137","author":"S Mabuchi","year":"2015","unstructured":"Mabuchi S, Kuroda H, Takahashi R, Sasano T . The PI3K\/AKT\/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol 2015; 137: 173\u2013179.","journal-title":"Gynecol Oncol"},{"key":"BFcdd2017129_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ygyno.2010.12.364","volume":"121","author":"JH No","year":"2011","unstructured":"No JH, Jeon YT, Park IA, Kim YB, Kim JW, Park NH et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol Oncol 2011; 121: 8\u201312.","journal-title":"Gynecol Oncol"},{"key":"BFcdd2017129_CR5","doi-asserted-by":"publisher","first-page":"8313","DOI":"10.1074\/jbc.C500451200","volume":"281","author":"H Chong-Kopera","year":"2006","unstructured":"Chong-Kopera H, Inoki K, Li Y, Zhu T, Garcia-Gonzalo FR, Rosa JL et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J Biol Chem 2006; 281: 8313\u20138316.","journal-title":"J Biol Chem"},{"key":"BFcdd2017129_CR6","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","volume":"2","author":"EP Henske","year":"2016","unstructured":"Henske EP, Jozwiak S, Kingswood JC, Sampson JR, Thiele EA . Tuberous sclerosis complex. Nat Rev Dis Primers 2016; 2: 16035.","journal-title":"Nat Rev Dis Primers"},{"key":"BFcdd2017129_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J . Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003; 13: 1259\u20131268.","journal-title":"Curr Biol"},{"key":"BFcdd2017129_CR8","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/onc.2009.452","volume":"29","author":"MC Liang","year":"2010","unstructured":"Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010; 29: 1588\u20131597.","journal-title":"Oncogene"},{"key":"BFcdd2017129_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1471-2407-8-163","volume":"8","author":"S Chakraborty","year":"2008","unstructured":"Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A . Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008; 8: 163.","journal-title":"BMC Cancer"},{"key":"BFcdd2017129_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/ncb839","volume":"4","author":"K Inoki","year":"2002","unstructured":"Inoki K, Li Y, Zhu T, Wu J, Guan KL . TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648\u2013657.","journal-title":"Nat Cell Biol"},{"key":"BFcdd2017129_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2007.05.058","volume":"130","author":"DF Lee","year":"2007","unstructured":"Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007; 130: 440\u2013455.","journal-title":"Cell"},{"key":"BFcdd2017129_CR12","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/jcmm.12380","volume":"18","author":"L Song","year":"2014","unstructured":"Song L, Su M, Wang S, Zou Y, Wang X, Wang Y et al. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med 2014; 18: 2266\u20132274.","journal-title":"J Cell Mol Med"},{"key":"BFcdd2017129_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejca.2005.03.023","volume":"41","author":"WG Jiang","year":"2005","unstructured":"Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005; 41: 1628\u20131636.","journal-title":"Eur J Cancer"},{"key":"BFcdd2017129_CR14","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jso.23585","volume":"109","author":"SJ Byeon","year":"2014","unstructured":"Byeon SJ, Han N, Choi J, Kim MA, Kim WH . Prognostic implication of TSC1 and mTOR expression in gastric carcinoma. J Surg Oncol 2014; 109: 812\u2013817.","journal-title":"J Surg Oncol"},{"key":"BFcdd2017129_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.3892\/or.2015.4099","volume":"34","author":"H Jiang","year":"2015","unstructured":"Jiang H, Yu WW, Wang LL, Peng Y . miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncol Rep 2015; 34: 1153\u20131161.","journal-title":"Oncol Rep"},{"key":"BFcdd2017129_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MAJ.0b013e3181e892a0","volume":"340","author":"XC Wang","year":"2010","unstructured":"Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ, Zhang H et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci 2010; 340: 385\u2013388.","journal-title":"Am J Med Sci"},{"key":"BFcdd2017129_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/cr.2015.98","volume":"25","author":"S Shen","year":"2015","unstructured":"Shen S, Guo X, Yan H, Lu Y, Ji X, Li L et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. Cell Res 2015; 25: 997\u20131012.","journal-title":"Cell Res"},{"key":"BFcdd2017129_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/path.4000","volume":"228","author":"Z Liu","year":"2012","unstructured":"Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012; 228: 204\u2013215.","journal-title":"J Pathol"},{"key":"BFcdd2017129_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/onc.2012.55","volume":"32","author":"K Boll","year":"2013","unstructured":"Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM et al. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 2013; 32: 277\u2013285.","journal-title":"Oncogene"},{"key":"BFcdd2017129_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00432-010-0918-4","volume":"137","author":"W Gao","year":"2011","unstructured":"Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y . MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011; 137: 557\u2013566.","journal-title":"J Cancer Res Clin Oncol"},{"key":"BFcdd2017129_CR21","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1073\/pnas.051042298","volume":"98","author":"ON Ozes","year":"2001","unstructured":"Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE et al. A phosphatidylinositol 3-kinase\/Akt\/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA 2001; 98: 4640\u20134645.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcdd2017129_CR22","doi-asserted-by":"publisher","first-page":"25227","DOI":"10.1074\/jbc.M114.554881","volume":"289","author":"HC Dan","year":"2014","unstructured":"Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS . Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IkappaB kinase alpha (IKKalpha). J Biol Chem 2014; 289: 25227\u201325240.","journal-title":"J Biol Chem"},{"key":"BFcdd2017129_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ccr.2006.08.007","volume":"10","author":"S Ghosh","year":"2006","unstructured":"Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Bist P et al. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 2006; 10: 215\u2013226.","journal-title":"Cancer Cell"},{"key":"BFcdd2017129_CR24","doi-asserted-by":"publisher","first-page":"5308170","DOI":"10.1155\/2016\/5308170","volume":"2016","author":"MH Bao","year":"2016","unstructured":"Bao MH, Li JM, Luo HQ, Tang L, Lv QL, Li GY et al. NF-kappaB-regulated miR-99a modulates endothelial cell inflammation. Mediators Inflamm 2016; 2016: 5308170.","journal-title":"Mediators Inflamm"},{"key":"BFcdd2017129_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.4161\/auto.9064","volume":"5","author":"H Zhu","year":"2009","unstructured":"Zhu H, Wu H, Liu X, Li B, Chen Y, Ren X et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 2009; 5: 816\u2013823.","journal-title":"Autophagy"},{"key":"BFcdd2017129_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4161\/auto.8.2.18351","volume":"8","author":"G Korkmaz","year":"2012","unstructured":"Korkmaz G, le Sage C, Tekirdag KA, Agami R, Gozuacik D . miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. Autophagy 2012; 8: 165\u2013176.","journal-title":"Autophagy"},{"key":"BFcdd2017129_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4161\/auto.23117","volume":"9","author":"KA Tekirdag","year":"2013","unstructured":"Tekirdag KA, Korkmaz G, Ozturk DG, Agami R, Gozuacik D . MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5. Autophagy 2013; 9: 374\u2013385.","journal-title":"Autophagy"},{"key":"BFcdd2017129_CR28","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1038\/emboj.2011.331","volume":"30","author":"LB Frankel","year":"2011","unstructured":"Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A et al. microRNA-101 is a potent inhibitor of autophagy. EMBO J 2011; 30: 4628\u20134641.","journal-title":"EMBO J"},{"key":"BFcdd2017129_CR29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1182\/blood-2011-02-336487","volume":"118","author":"A Meenhuis","year":"2011","unstructured":"Meenhuis A, van Veelen PA, de Looper H, van Boxtel N, van den Berge IJ, Sun SM et al. MiR-17\/20\/93\/106 promote hematopoietic cell expansion by targeting sequestosome 1-regulated pathways in mice. Blood 2011; 118: 916\u2013925.","journal-title":"Blood"},{"key":"BFcdd2017129_CR30","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/0008-5472.CAN-11-3671","volume":"72","author":"V Kovaleva","year":"2012","unstructured":"Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, Bartenschlager R et al. miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res 2012; 72: 1763\u20131772.","journal-title":"Cancer Res"},{"key":"BFcdd2017129_CR31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jhep.2016.06.028","volume":"65","author":"C Brisac","year":"2016","unstructured":"Brisac C, Salloum S, Yang V, Schaefer EA, Holmes JA, Chevaliez S et al. IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-kappaB pathway. J Hepatol 2016; 65: 972\u2013979.","journal-title":"J Hepatol"}],"container-title":["Cell Death & Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cdd2017129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2017129","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cdd.2017.129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2017129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:12:07Z","timestamp":1684415527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cdd2017129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["BFcdd2017129"],"URL":"https:\/\/doi.org\/10.1038\/cdd.2017.129","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]},"assertion":[{"value":"4 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}